(UroToday.com) Genomic characterization of bladder carcinoma in situ (CIS) mostly has been in the context of concurrent papillary tumors, and not necessarily unique CIS. Dr. Noah Hahn presented results investigating the feasibility of obtaining high-quality transcriptome data from CIS specimens utilizing the novel extraction-free EdgeSeq Precision Immuno-Oncology Panel (PIP) platform.